Evidence map›Paper›PMID 33819365›Full record

ArticlePathology international2021

Difference in the distribution of tumor-infiltrating CD8+ T cells and FOXP3+ T cells between micronodular thymoma with lymphoid stroma and micronodular thymic carcinoma with lymphoid stroma.

Haruna Yagi, Masato Nakaguro, Masafumi Ito, Yuki Okumura, Seishiro Takahashi, Yoichiro Aoshima, Yasunori Enomoto, Shiori Meguro, Hideya Kawasaki, Isao Kosugi and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Pathology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Haruna YagiDepartment of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.ORCID http://orcid.org/0000-0002-4647-1639
Masato NakaguroDepartment of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.ORCID http://orcid.org/0000-0001-6987-3043
Masafumi ItoDepartment of Pathology, Japanese Red Cross, Nagoya First Hospital, Nagoya, Japan.ORCID http://orcid.org/0000-0002-3553-4104
Yuki OkumuraDepartment of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.
Seishiro TakahashiDepartment of Diagnostic Pathology, Seirei Mikatahara Hospital, Hamamatsu, Japan.
Yoichiro AoshimaDepartment of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Yasunori EnomotoDepartment of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Shiori MeguroDepartment of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.ORCID http://orcid.org/0000-0002-5473-2608
Hideya KawasakiInstitute for NanoSuit Research, Preeminent Medical Photonics Education and Research Center, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Isao KosugiDepartment of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Yoshie ShimoyamaDepartment of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.
Hiroshi OgawaDepartment of Diagnostic Pathology, Seirei Mikatahara Hospital, Hamamatsu, Japan.
Hisashi TateyamaDepartment of Pathology, Clinical Laboratory, Kasugai Municipal Hospital, Kasugai, Japan.
Toshihide IwashitaDepartment of Regenerative and Infectious Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hamamatsu University School of Medicine · JPNagoya University Hospital · JPSeirei Mikatabara General Hospital · JPJapanese Red Cross Nagoya Daiichi Hospital · JPKasugai Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Micronodular thymoma with lymphoid stroma (MNT) is a rare thymic epithelial neoplasm subtype characterized by a micronodular tumor cell growth pattern and abundant lymphoid stroma. Micronodular thymic carcinoma with lymphoid stroma (MNCA) is considered as a malignant counterpart of MNT and exhibits a growth pattern similar to that of MNT but has histologic features reminiscent of thymic squamous cell carcinoma, such as cytologic atypia and CD5 and CD117 immunoexpression. Although both MNT and MNCA are characterized by abundant lymphoid stroma, it remains unknown whether there are differences in infiltrating lymphocytes between MNT and MNCA. We analyzed the immune microenvironment profile in eight MNT and three MNCA cases. The cell density of CD8-positive T cells was significantly higher in MNT than in MNCA, whereas that of FOXP3-positive T cells was significantly higher in MNCA than in MNT. There was no significant difference in the cell density of programmed death protein 1-positive T cells and programmed death ligand 1 expression between the MNT and MNCA cases. Our findings indicated that the immune microenvironment of MNCA differed from that of MNT and, compared with the T-cell profile of MNT, that of MNCA was more suppressive to patients' antitumor immune response.

Indexed as

Neoplasms, Glandular and EpithelialThymomaThymus NeoplasmsAdolescentAdultB7-H1 AntigenB-LymphocytesCD8-Positive T-LymphocytesCytodiagnosisDiagnosis, DifferentialForkhead Transcription FactorsHumansHyperplasiaImmunohistochemistryLymphocyte CountLymphocytes, Tumor-InfiltratingB7-H1 AntigenForkhead Transcription FactorsFOXP3 protein, humanCD8FOXP3micronodular thymic carcinoma with lymphoid stromamicronodular thymoma with lymphoid stromaPD-1PD-L1thymic epithelial tumortumor-infiltrating lymphocytetumor microenvironment

Identifiers

PMID33819365
PMCPMC8359975
OpenAlexW3141982101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.